Envudeucitinib vs Lomedeucitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

Envudeucitinib

Developed by Alumis and partners

Phase 3 in Psoriasissmall molecule
Reliable signal

NCT06586112 · Phase 3 · completed

Participants were randomized and blinded across drug, placebo, and active-comparator arms. A much larger share of patients on envudeucitinib achieved high levels of skin clearance than on placebo, with a highly significant difference.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2027 · NCT05739435 (registry estimate)

Reported efficacy

To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo (16 weeks): PASI-75 at week 16 (ONWARD 1): 76.5% envudeucitinib vs 18.7% placebo; PASI-90: 59.9% vs 4.8%; PASI-100: 29.4% vs 0.9% (P<.0001 for all) (met)

Result source: NCT06586112

Lomedeucitinib

Developed by Beeline Medicines under a licence from Bristol-Myers Squibb

Phase 2 in Psoriasissmall molecule
Partial signal

NCT05730725 · Phase 2 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and included 109 participants, but each treatment group was relatively small. The clinical primary endpoint, PASI-75 response at week 12, favored BMS-986322 over placebo based on the reported rates, although statistical significance was not reported in the registry.

Reported efficacy

Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks); Number of Participants With Safety Related Events (approximately 85 days); Number of Participants With TEAE by Worst Intensity (approximately 5 months); Number of Participants With AE Indicating Clinical Laboratory Abnormality (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in ECG Evaluations. (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Evaluations (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Evaluations (approximately 5 months): Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks): BMS-986322 16 mg 47.8% (95% CI 26.8 to 69.4) | BMS-986322 32 mg 80.8% (95% CI 60.6 to 93.4) | BMS-986322 64 mg 63% (95% CI 42.4 to 80.6) vs Placebo 3.6% (95% CI 0.1 to 18.3) (met)

Result source: NCT05730725

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEnvudeucitinibLomedeucitinib
PASI 7556.4% vs 0%+56.4 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 64.1% vs 0% 40mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 33.3% vs 0% 20mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
  • 56.4% vs 0% 20mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 19.4% vs 0% 10mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
63% vs 3.6%+59.4 vs placebowk 12 · n 27NCT05730725
17 other results
  • 80.8% vs 3.6% wk 12 · n 26 · Phase 2 · primary NCT05730725
  • 47.8% vs 3.6% wk 12 · n 23 · Phase 2 · primary NCT05730725
  • 72% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 57.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 4% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 3.8% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 80.8% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 66.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 33.3% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 11.5% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 54.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 40% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.4% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
PASI 90—Not posted · NCT0658873840.7% vs 3.6%+37.1 vs placebowk 12 · n 27NCT05730725
17 other results
  • 48% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 61.5% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 61.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 25.9% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 18.5% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 13% vs 3.6% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 13.6% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
PASI 100—Not posted · NCT065887383.7% vs 0%+3.7 vs placebowk 12 · n 27NCT05730725
17 other results
  • 4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
sPGA 0/153.8% vs 7.9%+45.9 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 59% vs 7.9% 40mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 38.9% vs 7.9% 20mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
  • 48.7% vs 7.9% 20mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 16.7% vs 7.9% 10mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
55.6% vs 3.6%+52 vs placebowk 12 · n 27NCT05730725
2 other results
  • 69.2% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 54.2% vs 3.6% wk 12 · n 24 · Phase 2 · secondary NCT05730725
DLQI, change—Not posted · NCT06588738—Not reported

PASI 75

Envudeucitinib
56.4% vs 0%+56.4 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 64.1% vs 0% 40mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 33.3% vs 0% 20mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
  • 56.4% vs 0% 20mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 19.4% vs 0% 10mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
Lomedeucitinib
63% vs 3.6%+59.4 vs placebowk 12 · n 27NCT05730725
17 other results
  • 80.8% vs 3.6% wk 12 · n 26 · Phase 2 · primary NCT05730725
  • 47.8% vs 3.6% wk 12 · n 23 · Phase 2 · primary NCT05730725
  • 72% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 57.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 4% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 3.8% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 80.8% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 66.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 33.3% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 11.5% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 54.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 40% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.4% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725

PASI 90

Envudeucitinib
—Not posted · NCT06588738
Lomedeucitinib
40.7% vs 3.6%+37.1 vs placebowk 12 · n 27NCT05730725
17 other results
  • 48% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 61.5% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 61.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 25.9% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 18.5% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 13% vs 3.6% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 13.6% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725

PASI 100

Envudeucitinib
—Not posted · NCT06588738
Lomedeucitinib
3.7% vs 0%+3.7 vs placebowk 12 · n 27NCT05730725
17 other results
  • 4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725

sPGA 0/1

Envudeucitinib
53.8% vs 7.9%+45.9 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 59% vs 7.9% 40mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 38.9% vs 7.9% 20mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
  • 48.7% vs 7.9% 20mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 16.7% vs 7.9% 10mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
Lomedeucitinib
55.6% vs 3.6%+52 vs placebowk 12 · n 27NCT05730725
2 other results
  • 69.2% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 54.2% vs 3.6% wk 12 · n 24 · Phase 2 · secondary NCT05730725

DLQI, change

Envudeucitinib
—Not posted · NCT06588738
Lomedeucitinib
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Envudeucitinib: 4 of 4 rows · Lomedeucitinib: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEnvudeucitinibLomedeucitinib
Dropout rate
10.3%40mg BIDa
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
15.4%40mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
7.5%20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
16.7%20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
7.4%BMS-986322 64 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
3.7%BMS-986322 32 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7%BMS-986322 16 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
Discontinued due to AEs
2.6%40mg BIDa
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
2.6%40mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
5.6%20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
—BMS-986322 64 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
—BMS-986322 32 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
—BMS-986322 16 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
Serious AEs
0%40mg BIDa
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
2.6%40mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
7.7%20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
0%20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
2.8%10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%BMS-986322 64 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
0%BMS-986322 32 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7%BMS-986322 16 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
Most frequent reported AEs
40mg BIDa
headache 7.7% (placebo 5.3%)
nasopharyngitis 7.7% (placebo 7.9%)
upper respiratory tract infection 7.7% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
40mg QD
headache 10.3% (placebo 5.3%)
acne 5.1% (placebo 0%)
upper respiratory tract infection 5.1% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
20mg BID
headache 7.7% (placebo 5.3%)
cough 5.1% (placebo 0%)
diarrhea 5.1% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
20mg QD
headache 5.6% (placebo 5.3%)
upper respiratory tract infection 5.6% (placebo 0%)
acne 0% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
10mg QD
diabetes mellitus 5.6% (placebo 0%)
nasopharyngitis 5.6% (placebo 7.9%)
upper respiratory tract infection 5.6% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
acne 14.8% (placebo 0%)
covid-19 11.1% (placebo 0%)
dermatitis acneiform 7.4% (placebo 0%)
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
aphthous ulcer 11.1% (placebo 0%)
folliculitis 11.1% (placebo 0%)
upper respiratory tract infection 7.4% (placebo 0%)
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
diarrhoea 7.4% (placebo 0%)
headache 7.4% (placebo 0%)
influenza 7.4% (placebo 3.6%)
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lomedeucitinib

PASI 50 81.5% (n=27) vs 17.9% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
7.7% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
24% (n=27) vs 12% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
65.4% (n=27) vs 10.7% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
88.5% (n=27) vs 8% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
92% (n=27) vs 20.8% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
92.3% (n=26) vs 17.9% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
7.7% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
34.6% (n=27) vs 12% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
66.7% (n=27) vs 10.7% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
85.2% (n=27) vs 8% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
92.3% (n=27) vs 20.8% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
73.9% (n=23) vs 17.9% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.8% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
14.8% (n=27) vs 12% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
48.1% (n=27) vs 10.7% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
84% (n=27) vs 8% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
81.8% (n=27) vs 20.8% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI 90 40.7% (n=27) vs 3.6% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
7.7% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
30.8% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
48% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
61.5% (n=26) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
18.5% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
25.9% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
61.5% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
13% (n=23) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
8% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
13.6% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI 100 3.7% (n=27) vs 0% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
4% (n=27) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
15.4% (n=26) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7% (n=27) vs 0% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
15.4% (n=27) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=23) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI -3.36 vs -0.5 placebo score @ 1wk
absolute change · score
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 14 more results
-6.27 vs -3.3 placebo score @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-10.05 vs -3.97 placebo score @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.06 vs -3.73 placebo score @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-15.44 vs -4.43 placebo score @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-2.95 vs -0.5 placebo score @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-7.13 vs -3.3 placebo score @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-10.63 vs -3.97 placebo score @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.66 vs -3.73 placebo score @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-15.39 vs -4.43 placebo score @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-2.85 vs -0.5 placebo score @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-5.16 vs -3.3 placebo score @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-8.53 vs -3.97 placebo score @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.34 vs -3.73 placebo score @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.55 vs -4.43 placebo score @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Envudeucitinib's landscape · Lomedeucitinib's landscape